Cover Image
市場調查報告書

黃熱病:開發中產品分析

Yellow Fever - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 246029
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
黃熱病:開發中產品分析 Yellow Fever - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 66 Pages
簡介

黃熱病是由黃熱病毒所引起的急性全身性出血熱傳染病,其媒介為蚊子。常見的症狀包含心律不整、出血、嘔吐、昏睡、譫妄症、發熱、頭痛及肌肉痛。黃熱病沒有特別的治療方法,但可接受緩和症狀用治療。

本報告提供黃熱病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

黃熱病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

黃熱病:企業開發中的治療藥

黃熱病:大學/機關研究中的治療藥

黃熱病:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

黃熱病:企業開發中的產品

黃熱病:大學/機關研究中的產品

黃熱病的治療藥的開發企業

  • Adamas Pharmaceuticals, Inc.
  • Arno Therapeutics, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • iBio, Inc.
  • Johnson & Johnson
  • NewLink Genetics Corporation
  • Panacea Biotec Limited
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Themis Bioscience GmbH
  • Valneva SE

黃熱病:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

黃熱病:最近的開發平台趨勢

黃熱病:暫停中的計劃

黃熱病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8571IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Yellow Fever - Pipeline Review, H2 2016, provides an overview of the Yellow Fever (Infectious Disease) pipeline landscape.

Yellow fever is an acute systemic illness (hemorrhagic fever) caused by the Flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There is no specific treatment for yellow fever but can be treated to relieve the symptoms.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Yellow Fever - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Yellow Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Yellow Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 8 and 5 respectively for Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively for Yellow Fever.

Yellow Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Yellow Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Yellow Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Yellow Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Yellow Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Yellow Fever (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Yellow Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Yellow Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Yellow Fever Overview
  • Therapeutics Development
    • Pipeline Products for Yellow Fever - Overview
    • Pipeline Products for Yellow Fever - Comparative Analysis
  • Yellow Fever - Therapeutics under Development by Companies
  • Yellow Fever - Therapeutics under Investigation by Universities/Institutes
  • Yellow Fever - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Yellow Fever - Products under Development by Companies
  • Yellow Fever - Products under Investigation by Universities/Institutes
  • Yellow Fever - Companies Involved in Therapeutics Development
    • Arno Therapeutics, Inc.
    • Bavarian Nordic A/S
    • BioCryst Pharmaceuticals, Inc.
    • Ennaid Therapeutics, LLC
    • iBio, Inc.
    • Johnson & Johnson
    • NewLink Genetics Corporation
    • Panacea Biotec Limited
    • Sihuan Pharmaceutical Holdings Group Ltd.
    • Valneva SE
  • Yellow Fever - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (arenavirus + yellow fever) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BCX-4430 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DEF-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JK-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RKP-00156 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Yellow Fever - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XRX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever [strain YF17D] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yellow fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Yellow Fever - Dormant Projects
  • Yellow Fever - Product Development Milestones
    • Featured News & Press Releases
      • Jul 27, 2016: Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine
      • Jul 27, 2016: NIH launches early-stage yellow fever vaccine trial
      • Apr 07, 2011: Xcellerex Announces Positive Results From Phase I Clinical Trial Of XRX-001
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Yellow Fever, H2 2016
  • Number of Products under Development for Yellow Fever - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Yellow Fever - Pipeline by Arno Therapeutics, Inc., H2 2016
  • Yellow Fever - Pipeline by Bavarian Nordic A/S, H2 2016
  • Yellow Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2016
  • Yellow Fever - Pipeline by Ennaid Therapeutics, LLC, H2 2016
  • Yellow Fever - Pipeline by iBio, Inc., H2 2016
  • Yellow Fever - Pipeline by Johnson & Johnson, H2 2016
  • Yellow Fever - Pipeline by NewLink Genetics Corporation, H2 2016
  • Yellow Fever - Pipeline by Panacea Biotec Limited, H2 2016
  • Yellow Fever - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2016
  • Yellow Fever - Pipeline by Valneva SE, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Yellow Fever - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Yellow Fever, H2 2016
  • Number of Products under Development for Yellow Fever - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top